Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.60 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 11/20 | 0.58 |
| ▸ | GAK | O14976 | 3/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075809 | 0.92 | PTK6 (0.60) | ALKPTK6EGFRGAKGRM4 | |
| SCHEMBL17075805 | 0.89 | EGFR (0.74) | EGFRGAKERBB2 | |
| SCHEMBL17075846 | 0.86 | PTK6 (0.51) | ALKPTK6EGFRGAKGRM4 | |
| SCHEMBL17075864 | 0.81 | EGFR (0.74) | EGFRGAKERBB2 | |
| SCHEMBL17075854 | 0.81 | GRM4 (0.53) | PTK6EGFRGAKGRM4ERBB2 | |
| SCHEMBL17075845 | 0.80 | PTK6 (0.51) | PTK6EGFRGAKGRM4ERBB2 | |
| SCHEMBL17075874 | 0.79 | GRM4 (0.53) | PTK6EGFRGAKGRM4ERBB2 | |
| SCHEMBL7015701 | 0.79 | ALK (0.78) | ALKEGFRGAKRIPK2TGFBR1 | |
| SCHEMBL5253967 | 0.79 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL17083354 | 0.78 | EGFR (0.62) | PTK6EGFRGAKRIPK2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | TPP1, MKI67, PIGO | ALK 4884/4885PTK6 1406/4885EGFR 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.